Can a ChondroFiller injection help at Grade III or IV knee OA?

For patients with Kellgren-Lawrence Grade III or IV knee osteoarthritis, ChondroFiller injection is being used as a joint-preservation pathway — an attempt to support the remaining joint environment and slow progression before knee replacement becomes the only option. The short answer to whether it can help is: in selected patients, yes, but the evidence is still building and expectations need to be set carefully from the outset.

At KL Grade III and IV, cartilage loss is no longer confined to a small, contained patch. The wear is diffuse, often affecting multiple zones of the joint surface simultaneously. That pattern matters, because the conventional cartilage repair toolkit — microfracture, ACI, MACI — was designed around focal, bordered defects, not widespread degradation. ChondroFiller injection works differently: delivered as an ultrasound-guided outpatient procedure (no general anaesthetic, no theatre), the injectable collagen scaffold gels across degraded surfaces and supports the body's own repair processes through matrix-induced chondrogenesis.

This is a preservation pathway, not a restoration. It is suited to patients who retain some cartilage tissue and biological capacity for cell recruitment, and who are aiming to delay or avoid joint replacement. Whether a specific patient qualifies requires a consultant-led assessment with MRI evidence.

Why diffuse OA damage is structurally different from a focal defect

The Kellgren-Lawrence scale runs from Grade I (minor bony changes, no significant cartilage loss) through to Grade IV, where joint-space narrowing is severe and the bones are effectively in contact. At Grade III, cartilage has suffered partial-thickness loss across meaningful areas of the joint surface, with visible osteophyte formation and narrowing on imaging. By Grade IV, remaining cartilage is minimal and subchondral bone has begun to remodel in response to the altered load — changes that are not simply cosmetic on MRI but reflect a fundamentally altered joint environment.

The geometric problem this creates is important. Techniques such as microfracture, ACI, and MACI were designed to fill a discrete, contained cavity — one bordered by intact, healthy cartilage on all sides. That surrounding tissue acts as a wall, stabilising the repair material and providing the biological signals the repair site needs. In advanced diffuse OA, that geometry does not exist. Damage typically spans the medial compartment, the lateral compartment, and the patellofemoral surface in varying combinations — not one hole to fill, but a surface that has degraded across multiple zones simultaneously.

At Grade IV in particular, viable chondrocyte density is reduced and the subchondral bone architecture has changed, narrowing the window of biological capacity available to any repair strategy. This is the structural reality that any treatment in this setting must contend with.

How ChondroFiller injection works across a degraded joint surface

Delivered under ultrasound guidance as an outpatient injection, ChondroFiller® begins working the moment it reaches the joint. Within three to five minutes of placement, the acellular Type I collagen hydrogel transitions from a liquid state to a soft, porous three-dimensional scaffold — gelling directly on the articular surface without any surgically prepared cavity beneath it.

This is the practical significance of what the manufacturer terms 'top-down gelation'. Rather than plugging a bordered hole, the scaffold drapes and conforms across irregular, degraded cartilage — behaving more like a conforming membrane than a rigid implant. For a joint where wear is distributed across multiple zones, as in KL Grade III and IV disease, that geometry matters: the material can adhere to surfaces that no focal-repair technique would attempt to address in a single procedure.

Critically, no donor cells are injected alongside the scaffold. ChondroFiller is acellular — it contains no stem cells or chondrocytes of its own. Instead, the porous matrix acts as a recruitment platform, drawing the patient's own progenitor cells inward from the synovium and subchondral bone through a process called matrix-induced acellular chondrogenesis. Once inside the scaffold, these cells begin depositing collagen and glycosaminoglycans — the structural proteins that give healthy cartilage its load-bearing properties.

Mechanistic support for this sequence comes from a 2025 ex vivo osteochondral explant study (n=61 explants), which found that ChondroFiller alone produced a 2.4-fold increase in DNA content within the scaffold by day 14 — direct evidence of cell migration into the matrix. When mesenchymal stem cells were added alongside the scaffold, collagen deposition and glycosaminoglycan production increased further, providing the laboratory rationale for combination protocols in more advanced presentations.

What the clinical evidence shows — and where gaps remain

Three bodies of evidence are directly relevant here, and they sit at different levels of confidence.

The most applicable data comes from a 2025 prospective controlled trial by Weninger et al. at Avancell Medical in Vienna, which enrolled 25 patients with Kellgren-Lawrence Grade IV knee OA. In that cohort, ChondroFiller® Liquid combined with autologous blood-derived MSC concentrate produced measurably greater improvements in pain and function at two months compared with MSC concentrate alone — with both treatments delivered as injections, without surgery or general anaesthesia. The trial is the only study to enrol specifically this population, which makes it the most relevant reference available. Its limitations are equally specific: the cohort is small, the allocation was not randomised, and two months is too short a horizon to draw conclusions about durability or joint-replacement postponement.

Two earlier studies extend the picture but from a different patient group. The 2016 multicenter RCT — 13 ChondroFiller patients versus 10 microfracturing — demonstrated significant IKDC improvement at three and six months (p<0.05), sustained to 12 months, with MRI confirming progressive cartilage maturation and no adverse events. A 2024 Bulgarian series (n=17, 12-month follow-up) showed comparable Lysholm and IKDC gains, with scores plateauing between six and twelve months rather than continuing to rise. Both studies support the scaffold's safety and biological activity — but both enrolled patients with focal, contained defects, not the diffuse multi-zone wear of Grade III/IV OA.

A 2024 biomechanical study adds a constraint that matters particularly in bone-on-bone joints. Testing porcine osteochondral cylinders under cyclic 33 N loading, researchers found that ChondroFiller did not reduce damage to the opposing cartilage surface — a finding the authors attributed to initial material instability rather than fundamental failure. The clinical implication is practical: full weight-bearing must be deferred until the scaffold has achieved stable integration, which is especially important in Grade IV joints already under high mechanical demand.

The closest analogue for longer-term outcomes in established widespread degeneration comes from a different joint entirely. A 2021 hip arthroscopy cohort (n=26, follow-up 12–60 months) found that 17 of 21 available patients had good or excellent results — but those with pre-existing hip OA at Tönnis grade 2 or 3 (the hip equivalent of advanced KL disease) fared poorly. This is the only multi-year signal suggesting that established, diffuse degeneration may blunt scaffold efficacy across joints, and it warrants honest acknowledgement.

Taken together, these studies support the biological rationale but leave a clear gap: no large randomised controlled trial has yet tested ChondroFiller specifically in diffuse KL Grade III/IV knee OA with long-term follow-up. Candidacy assessment by an experienced clinician remains the appropriate starting point, not expectation of guaranteed outcomes.

Combination protocols for advanced OA: from Dual Injection to Tri-Active Therapy

Advanced OA is rarely a single-problem joint. By KL Grade III or IV, cartilage surface loss, synovial inflammation, and compromised mechanical environment often coexist — and a single injection addressing only one of these dimensions may leave others unresolved. The tiered protocols used at the London Cartilage Clinic reflect that reality.

The starting point for most advanced presentations is the Dual Injection protocol: a ChondroFiller® injection (2.3 mL, applied to the articular surfaces where bone meets bone under load) combined with Arthrosamid® (6 mL, delivered intra-articularly to the synovial environment). These two products are doing categorically different work. ChondroFiller is the regenerative scaffold component — a collagen matrix that supports acellular matrix-induced chondrogenesis, as described in the preceding sections. Arthrosamid is a polyacrylamide hydrogel (PAAG): it is non-regenerative, does not act as a cartilage scaffold, and targets the synovium to provide longer-lasting pain dampening. Collapsing them into one generic 'filler' category would misrepresent both mechanisms. Guide cost for the Dual Injection is approximately £6,000, to be confirmed at assessment.

For the most demanding presentations — where additional biological stimulus is judged necessary — the protocol escalates to a Tri-Active Therapy, adding an autologous MSC concentrate as a third component. The rationale for that addition is directly supported by the 2025 Weninger pilot: in 25 KL Grade IV patients, combining ChondroFiller® Liquid with blood-derived MSC concentrate produced measurably greater functional gains than MSCs alone, suggesting an additive biological effect rather than simple overlap. Guide cost for this combination is approximately £11,000.

Suitability for either protocol — and which tier is appropriate — is determined at a consultant-led assessment, not by symptom severity alone.

Who is suitable — and what to expect at assessment

The patients most likely to benefit from a ChondroFiller injection at Grade III or IV are those who retain some viable joint tissue, have significant pain and functional limitation, and are aiming to preserve the joint before committing to replacement. Candidacy is confirmed at a consultant-led assessment with MRI evidence — symptom severity alone is not sufficient, and there is no fixed upper age limit.

Hard contraindications include active inflammatory arthritis (systemic), local joint infection, hypersensitivity to collagen or murine proteins, immunosuppression, and poorly controlled diabetes. Each of these undermines the biological environment on which the scaffold depends.

The bone-on-bone boundary condition warrants frank discussion at assessment. Where pan-articular degeneration at extreme Grade IV has depleted the viable cell population across the whole joint, the scaffold's recruitment capacity is diminished — as the hip OA evidence above illustrates. This is not an automatic exclusion, but the degree of remaining biological substrate must be weighed case by case.

Post-procedure loading is restricted, particularly in the early weeks. Biomechanical testing has shown that the scaffold is mechanically unstable before stable integration is achieved, which is the basis for careful weight-bearing protocols — especially in Grade IV joints already subject to high mechanical demand.

Outcome expectations should be anchored to stabilisation rather than full restoration. Published series show Lysholm and IKDC scores plateauing between six and twelve months, reflecting meaningful improvement in pain and function rather than complete cartilage regrowth.

The most productive assessment conversation covers the MRI-confirmed grade, whether pan-articular wear is present, which protocol tier fits the presentation, and what the realistic outcome range is given the current evidence. ChondroFiller injection is available in the UK at the London Cartilage Clinic on Harley Street; assessments can be arranged at londoncartilage.com.

1. [1] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Intra-Articular Injection of Human Bone Marrow–Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial. (2025). https://doi.org/10.1177/09636897241303275 https://doi.org/10.1177/09636897241303275
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z